Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 3, 2015, Pages 641-650

  Ying, Liu ^a   Chunxia, Yin ^b   Wei, Liu ^c  

^a Jilin Center of Newborn Screening   (China)

^b Changchun Obstetrics and Gynecology Hospital   (China)

^c Department of Obstetrics and Gynecology   (China)

Author keywords

LYTAK1; Mitochondrial permeability transition pore (mPTP); Necrosis; Ovarian cancer; TAK1

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CYCLOPHILIN D; CYCLOSPORIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; LYTAK1; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PACLITAXEL; SANGLIFEHRIN A; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN KINASE INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CASE REPORT; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; MIDDLE AGED; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; ASCITES; BAGG ALBINO MOUSE; DRUG SCREENING; ENZYMOLOGY; GENETIC TRANSFECTION; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; ASCITES; CELL LINE, TUMOR; FEMALE; HUMANS; MAP KINASE KINASE KINASES; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; RANDOM ALLOCATION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939574466     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2822-8     Document Type: Article

References (20)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9-29
2. Kipps E, Tan DS, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13(4):273-282
3. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11(10):719-725
4. Sakurai H (2012) Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 33(10):522-530
5. Martin SE, Wu ZH, Gehlhaus K, Jones TL, Zhang YW, Guha R, Miyamoto S, Pommier Y, Caplen NJ (2011) RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors. Curr Cancer Drug Targets 11(8):976-986
6. Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, Budillon A, Abbruzzese JL, Chiao PJ (2011) Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst 103(15):1190-1204
7. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber DA, Settleman J (2012) TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148(4):639-650
8. Ray DM, Myers PH, Painter JT, Hoenerhoff MJ, Olden K, Roberts JD (2012) Inhibition of transforming growth factor-beta-activated kinase-1 blocks cancer cell adhesion, invasion, and metastasis. Br J Cancer 107(1):129-136
9. Cai PC, Shi L, Liu VW, Tang HW, Liu IJ, Leung TH, Chan KK, Yam JW, Yao KM, Ngan HY, Chan DW (2014) Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-kappaB signaling. Oncotarget 5(17):7549-7562
10. Zhou J, Zheng B, Ji J, Shen F, Min H, Liu B, Wu J, Zhang S (2014) LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo. Tumour Biol 36(5):3301-3308
11. Zhu YR, Xu Y, Fang JF, Zhou F, Deng XW, Zhang YQ (2014) Bufotalin-induced apoptosis in osteoblastoma cells is associated with endoplasmic reticulum stress activation. Biochem Biophys Res Commun 451(1):112-118
12. Elrod JW, Molkentin JD (2013) Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ J 77(5):1111-1122
13. Halestrap AP (2006) Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem Soc Trans 34(Pt 2):232-237
14. Bonora M, Pinton P (2014) The mitochondrial permeability transition pore and cancer: molecular mechanisms involved in cell death. Front Oncol 4:302
15. Qiu Y, Yu T, Wang W, Pan K, Shi D, Sun H (2014) Curcumin-induced melanoma cell death is associated with mitochondrial permeability transition pore (mPTP) opening. Biochem Biophys Res Commun 448(1):15-21
16. Ji C, Yang B, Yang Z, Tu Y, Yang YL, He L, Bi ZG (2012) Ultra-violet B (UVB)-induced skin cell death occurs through a cyclophilin D intrinsic signaling pathway. Biochem Biophys Res Commun 425(4):825-829
17. Ataie-Kachoie P, Badar S, Morris DL, Pourgholami MH (2013) Minocycline targets the NF-kappaB Nexus through suppression of TGF-beta1-TAK1-IkappaB signaling in ovarian cancer. Mol Cancer Res 11(10):1279-1291
18. Halestrap AP, McStay GP, Clarke SJ (2002) The permeability transition pore complex: another view. Biochimie 84(2-3):153-166
19. Javadov S, Kuznetsov A (2013) Mitochondrial permeability transition and cell death: the role of cyclophilin d. Front Physiol 4:76
20. Hausenloy DJ, Lim SY, Ong SG, Davidson SM, Yellon DM (2010) Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning. Cardiovasc Res 88(1):67-74